Highest-materiality recent filing
CytoDyn extends $57M convertible notes maturity by 36 months, pays $1M/month in stock
Note 1 ($28.5M) maturity extended to April 5, 2029; Note 2 ($28.5M) to April 23, 2029.
CytoDyn raises $17.5M via private placement of 81.4M units at $0.2153 per unit
Private placement of ~81.4M units (share + warrant) to accredited investors for ~$17.5M in cash.
CytoDyn agrees to settle securities class action for $500K cash and 49M shares
Settlement in principle: $500,000 cash plus 49 million shares for dismissal of all claims.
CytoDyn secures $30M equity funding commitment from Yorkville Advisors over 36 months
Up to $30M in common stock sales to Yorkville over 36 months; company controls timing, no minimum draws.
CytoDyn settles Amarex lawsuit for $12M cash payment and $14M liability elimination
Amarex to pay CytoDyn $12 million total, with $10 million received upon execution.
CytoDyn reports unregistered sale of 52.6M units at $0.13/unit, diluting equity by >5%
52.6M units sold in private placement; 10.1M from note conversions, plus 1.5M follow-on units.
CytoDyn dismisses BF Borgers as auditor after SEC permanent bar; replacement search underway
Dismissed BF Borgers on May 6, 2024, following SEC order on May 3 permanently barring the firm.
On May 2, 2025, the Company entered into an agreement with Robert E. Hoffman (“Mr. Hoffman”), under which Mr. Hoffman will serve as the Company’s Chief Financial Officer (“CFO”), effective May 15, 2025 (the “Employment Agreement”).
Max materiality 0.85 · Median 0.70 · Most common event other_material